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Abstract. Two conditions were identified that inter- 
fered with the complex polymerization process in bio- 
synthesis of von WiUebrand factor (vWf). Treatment 
of human umbilical vein endothelial cells with tunica- 
mycin inhibited N-linked glycosylation of nascent 
vWf and the resulting pro-vWf monomers failed to 
dimerize. The single subunits accumulated in the en- 
doplasmic reticulum and were neither processed fur- 
ther nor secreted. In the presence of a weak base (am- 
monium chloride or chloroquine), interdimer disul- 
fide bond formation was inhibited in a dose-depend- 
ent manner. This process appeared therefore to be pH 
sensitive and likely to be initiated in the acidic trans- 
Golgi apparatus (Anderson, R. G. W., and R. K. Pa- 
thak, 1985, Cell, 40:635-643). The weak base had no 
obvious effect on the other processing steps, i.e. di- 
merization, complex carbohydrate formation and sul- 
fation, and produced only slight inhibition of pro- 
sequence cleavage. On the other hand, the weak base 
interfered with the targeting of newly synthesized vWf 
into Weibel-Palade bodies, with all of the vWf being 
secreted constitutively and none stored in the Weibel- 
Palade bodies. In summary, initial glycosylation of the 
nascent vWf protein and low pH in the trans-Golg~ 
apparatus were important conditions for the successful 
polymerization of human vWf. Genetic defects dis- 
rupting any one of these conditions could result in the 
phenotype of von Willebrand disease. 
V 
ON Willebrand factor (vWf)  ~  is an adhesive glycopro- 
tein necessary  for binding platelets to subendothelium 
after vascular injury (12, 23, 30). vWf is synthesized 
as a large precursor (260,000-mol-wt) that contains high man- 
nose carbohydrate ( 17, 31). After dimer formation and trans- 
port to the Golgi apparatus, the carbohydrate is processed to 
the  complex type, the  propiece is cleaved, and interdimer 
disulfide bond formation begins (32). Carbohydrate process- 
ing is accompanied  by an apparent  increase in molecular 
weight of the precursor subunit to 275,000. These observed 
molecular weights of precursor subunits underestimate actual 
size by ~30,000-50,000,  as determined by the size of vWf 
cDNA clones that span the vWf messenger RNA (9). 
vWf is stored in the endothelial cells within specific organ- 
elles called Weibel-Palade bodies (34). Secreted vWf consists 
of a series of multimers that range in size from 0.5 to over 20 
x  106 daltons, depending upon the number of  dimers that are 
disulfide bonded. In type IIA yon Willebrand disease, only 
the large and intermediate  size multimers are lacking (22), 
but patient plasma does not support efficient attachment of 
platelets to subendothelium  (24), indicating that multimer 
size is  important  for  vWf biological activity. As  yet,  the 
cellular defects that are responsible for incomplete polymeri- 
zation of vWf in the type IIA von Willebrand disease are not 
known. 
Abbreviation  used in this paper: vWf, yon Willebrand factor. 
Although vWf multimerization is inhibited in vitro by the 
ionophore monensin, the latter affects all of the processing 
steps of  the Golgi apparatus (33). In the study presented here, 
we have interfered with the interdimer disulfide bond forma- 
tion more specifically  by increasing the pH of  the trans-Golgi 
apparatus and we show that inhibition of N-linked glycosyl- 
ation blocks the dimerization process of vWf  biosynthesis. 
Materials and Methods 
Cells and Culture Conditions 
Endothelial cells were obtained from human umbilical vein by mild proteolytic 
digestion as described previously (8, 34); only primary cultures were used. Cells 
were cultured in McCoy's 5A medium (Flow Laboratories, Inc., McLean, VA) 
containing 20% fetal bovine serum. Tunicamycin (Calbiochem-Behring Corp., 
San  Diego, CA)  was  dissolved  in  dimethyl  sulfoxide,  chloroquine  (Sigma 
Chemical  Co.,  St.  Louis,  MO)  in  water,  and  ammonium chloride  (Fisher 
Scientific Co., Rochester, NY) in culture medium.  Control  cells were treated 
with the solvent alone. In the case of tunicamycin,  cells were pre-treated for 
-14 h with the drug prior  to metabolic  labeling. For continuous metabolic 
labeling, cells were grown in the presence of [35S]methionine (25-40  uCi/ml, 
18.7 Ci/mmol; Amersham  Corp,  Arlington  Heights, IL). In one study, cells 
were labeled overnight with [35S]sodium sulfate (230 ~Ci/ml, 767 mCi/mmol; 
New England  Nuclear,  Boston  MA) in medium containing  dialyzed serum 
(20). 
Antisera 
Preparation  and  characterization  of antisera  against  human  vWf were  as 
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from Calbiochem-Behring  Corp. Monospecific  antifibronectin antiserum was 
a kind gift from Dr. R. O. Hynes (Massachusetts  Institute of Technology) (15). 
Ammonium Chloride Treatment of Cells for 
Fluorescence Microscopy 
Cells freshly obtained from the umbilical  vein were plated on glass coverslips; 
after 2 d, the medium was replaced with medium containing 5 mM ammonium 
chloride.  The cells were grown in this medium for 5 d  (with  one medium 
change) before being processed  for fluorescence  microscopy (34). The pH of 
the culture medium containing ammonium chloride was between 7.4-7.6 in 
all experiments. 
Pulse-Chase Experiments in the Presence 
of Tunicamycin 
All media contained l ug/ml of tunicamycin, and incubations were at 37"C. 
Cells were preincubated overnight in medium containing fetal bovine serum 
and for  15  min in serum-free medium. Medium was then removed and the 
cells were covered with  l  ml serum-free medium containing  1.5  mCi [~S]- 
methionine and incubated for 20  min. Cells  were  then  rinsed in  medium 
containing serum and incubated in this medium for varying lengths of time. 
Control cells were treated identically  except that all  media did not contain 
tunicamycin. 
Purification of v Wf 
vWf was  immunopurified as  described  previously  (32)  and  samples were 
analyzed by gel electrophoresis after the radioactive count was determined. 
Endoglycosidase  H Digestion 
The enzyme was a generous gift of Dr. P. W. Robbins (Massachusetts Institute 
of Technology)  and was purified  according to Tarentino et al. (28). Purified 
vWf was diluted in 0.1  M Tris buffer, pH 5.8, so that the final concentration 
of  SDS was <0.5%. Endoglycosidase H was added (3 #g/ml), and samples were 
incubated for 2 h at 37"C before analysis on gels. 
Electrophoresis  Gels 
SDS  polyacrylamide  gels were  prepared as described by Laemmli (14), and 
agarose horizontal slab gels were prepared using a solution of  2% agarose, 0.1% 
SDS in 0.05 M phosphate buffer at pH 7.0. 
Results 
Effect of Tunicamycin on vWf  Processing 
and Secretion 
Culturing of human  umbilical vein endomelial cells in  the 
presence of 1 ~g/ml tunicamycin, an antibiotic which prevents 
N-linked  glycosylation  by  inhibiting  the  formation  of the 
donor dolicol-sugar (27),  had a profound effect on vWf proc- 
essing and secretion (Fig.  I a). vWf  purified from control cells 
contained similar amounts of precursor (260,000-mol-wt) and 
cleaved (220,000-mol-wt) subunits. The tunicamycin-treated 
cells contained  only precursor subunits  and these were not 
secreted (Fig. 1  a, Medium). Secretion ofvWfwas not restored 
in the presence of the lysosomal enzyme inhibitor, leupeptine 
(3) (not shown). The precursor subunit from the tunicamycin- 
treated cells migrated more rapidly than the 260,000-mol-wt 
precursor  of control  cells  (Fig.  I a),  because  tunicamycin 
inhibited the addition  of N-linked carbohydrate to the pre- 
cursor.  That  most of the  high  mannose  carbohydrate was 
lacking  from the  subunit  was  verified by its  resistance  to 
endoglycosidase H  (Fig.  I b),  which  cleaves the  chitobiosyl 
unit  of high  mannose carbohydrate (2 l,  28).  Whereas  the 
migration  of 260,000-mol-wt  precursor  subunit  from  un- 
treated  cells,  which  contains  high  mannose  carbohydrate, 
increased after endoglycosidase treatment, that of precursor 
produced by tunicamycin-treated cells was unchanged. 
Figure  1.  (a) The  effect of tunicamycin  on  pro-vWf cleavage and 
secretion by human endothelial cells. Cells were incubated overnight 
in the presence (+) or in the absence (-) of 1 ug/ml of tunicamycin 
and then metabolically labeled with [3~S]methionine for 24 h  in the 
same medium, vWf was purified from the culture medium and cell 
lysates and analyzed on 5% polyacrylamide gels, autoradiographs of 
which  are  shown.  Tunicamycin-treated  cells  contained  precursor 
subunit but  no cleaved subunit (220).  Secretion of vWf was com- 
pletely inhibited in  tunicamycin-treated cells, in  that  the  medium 
lacked  the  precursor (275) and  cleaved  subunits  (220) that  were 
secreted in control cultures. (b) Digestion of pro-vWf synthesized in 
the presence of tunicamycin with endoglycosidase H.  vWf purified 
from cells treated in the presence (+) or absence of tunicamycin (-) 
was digested with endoglycosidase H  (E).  The 260,000-mol-wt pre- 
cursor subunit (260) in control cells contains high mannose carbo- 
hydrate (32); therefore endoglycosidase H  treatment produced a shift 
in  its migration towards a  smaller apparent molecular weight. The 
precursor  synthesized in  the  presence of tunicamycin  co-migrated 
with the endoglycosidase H-treated (260,000-mol-wt) precursor pres- 
ent in control cells, and no shift in migration occurred after enzymatic 
treatment. This indicates that tunicamycin inhibited the addition of 
N-linked carbohydrate. The 220,000-mol-wt subunit present in con- 
trol  cells  is  resistant to  endoglycosidase H  (32),  since  it  contains 
mature complex-type carbohydrate. 
The effect of tunicamycin on dimer formation was studied 
by pulse-chase experiments. Cells preincubated in  the pres- 
ence  of  1  ug/ml  of tunicamycin  were  labeled  with  [3~S]- 
methionine for 20 min. The cells were then chased in unla- 
beled medium for varying time intervals. Tunicamycin was 
present during the  labeling and the  chase periods.  Purified 
vWf  from treated and control cells was examined nonreduced 
on  4.5%  acrylamide  gels  (Fig.  2).  While  the  monomeric 
precursor in the control cells dimerized almost completely in 
the  first hour  from the  onset  of labeling, dimers were not 
formed in the tunicamycin-treated cells.  It appears therefore 
that initial glycosylation of vWf precursor monomers is re- 
quired for processing and secretion of vWf. 
Effect of a Weak Base on the Processing of v Wf 
Endothelial  cells  were  metabolically labeled  for  3  d  in  the 
presence of varying concentrations of ammonium chloride to 
determine whether any of the processing steps in vWf  biosyn- 
thesis are pH sensitive, vWfwas purified from culture medium 
and lysed cells and analyzed nonreduced (Fig.  3) or reduced 
(Fig. 4a) by gel electrophoresis. Ammonium chloride inhib- 
ited interdimer disulfide bond formation in a dose-dependent 
manner (Fig. 3) that was similar to that produced by monensin 
(33).  In contrast to monensin, however, carbohydrate proc- 
essing and precursor cleavage were not significantly affected 
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cells migrated at the same position as subunits from control 
cultures (Fig. 4a) and the secreted material was resistant to 
endoglycosidase H  (Fig. 4b),  indicating that these subunits 
contained complex-type carbohydrate. Sulfation of vWf (5) 
also was not inhibited by ammonium chloride (not shown). 
The ratios of precursor to mature subunit in secreted vWf 
were quantitated by densitometric scanning. In three inde- 
pendent experiments, precursor cleavage was inhibited only 
20% by 25 mM ammonium chloride, a concentration which 
completely inhibited  multimerization  ofvWfdimers. Concen- 
trations of 5 mM and higher depleted the endothelial cells of 
processed subunits (Fig. 4a) and small multimers (Fig.  3). 
The ratio of secreted to cell-associated vWfincreased  threefold 
in treated cells,  duplicating the  effect  seen with  monensin 
(33),  and reflected in the loss of Weibel-Palade bodies (Fig. 
5). It appears therefore that the multimerization of vWf and 
the formation of Weibel-Palade bodies from the Golgi appa- 
ratus (26) are pH dependent. The same results (not shown) 
were obtained with another weak base, chloroquine (10-50 
#M), using shorter labeling periods because of the toxic effect 
of chloroquine on cells.  The small multimers synthesized in 
the presence of 5 mM NH4C1 contained fully processed sub- 
units, but did not incorporate into endothelial cell extracel- 
lular matrix (Fig. 5), confirming prior observations that vWf 
multimer size is a crucial factor in this interaction (33). 
Figure 2. The effect of tunicamycin  on dimerization of wVf. Human 
umbilical vein endothelial cells were metabolically labeled for 20 min 
in the absence (-) or in the presence (+) of 1 #g/ml of tunicamycin 
and then chased in unlabeled medium,  vWf was purified from the 
lysed cells and examined nonreduced on a 4.5% acrylamide gel after 
autoradiography. Numbers indicate time in hours from the onset of 
labeling. In control cultures, monomeric vWf formed dimers, while 
in tunicamycin-treated cells the subunit remained monomeric. 
Figure 3. The effect of ammonium chloride on multimerization of 
vWf. Endothelial  cells were metabolically labeled for  3 d  in the 
presence of ammonium chloride, vWf was purified from the lysed 
cells and culture  media  and electrophoresed  nonreduced  on  2% 
agarose gels, autoradiographs of which are shown. Some of the  25 
mM ammonium chloride-treated  cells lifted prior to cell lysis and 
therefore less radioactivity was present in this sample. Ammonium 
chloride inhibited  interdimer  disulfide bond formation  in a dose- 
dependent manner and the small multimers produced in its presence 
were not stored in the cells. 
Figure 4. The effect of ammonium chloride on precur- 
sor cleavage and carbohydrate processing of vWf. (a) 
vWf purified from endothelial cells treated as in Fig. 3 
was analyzed reduced on 5% polyacrylamide gels. The 
autoradiograph shows that the majority of the pro-vWf 
subunits  were cleaved to the 220,000-mol-wt size in the 
presence of ammonium chloride and that the electro- 
phoretic migration of the subunits did not change with 
increasing concentration  of ammonium chloride. (b) 
Endothelial  cells were labeled for three  days in the 
presence of 25  mM  ammonium chloride,  and vWf 
purified  from  lysed cells and  culture  medium  was 
treated with endoglycosidase  H (E). Both of the secreted 
subunits (275 and 220) were endoglycosidase H resist- 
ant, indicating that the carbohydrate was processed to 
the complex type. As noted for untreated  cultures in 
Fig. I b, only the cellular precursor of 260,000-mol-wt 
was endoglycosidase H sensitive. 
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were grown on glass coverslips for 5 d in the absence (a) or presence (b and c) of 5 mM ammonium chloride. The cells were permeabilized 
and stained by immunofluorescence with anti-vWf antiserum (a and b) and with antifibronectin antiserum (c). The Weibel-Palade bodies 
(arrowhead) were absent from the treated cells (b). The ammonium chloride-treated  cells produced a fibronectin-containing extracellular 
matrix (c), but the small vWf multimers secreted by these cells (see Fig. 3) did not incorporate into this matrix (b). Bar, 20 t~m. 
Discussion 
Importance of  lnitial Glycosylation on Dimerization 
and Intracellular Transport of  Human vWf Subunits 
The inhibition of N-linked carbohydrate addition to the grow- 
ing polypeptide chain  of vWf by tunicamycin appeared to 
have a profound effect on its subsequent fate. It is likely that 
the carbohydrate provides the vWf monomer with a confor- 
mation that favors dimerization. The presence oftunicamycin 
inhibited  the  formation of dimers entirely (Fig.  2)  and  no 
subsequent processing of the pro-vWf monomers took place, 
i.e., the pro-sequence was not cleaved and the monomers were 
not  secreted.  220,000-mol-wt  monomers are  not  found  in 
untreated  endothelial  cells,  nor  are  they  secreted  (32).  It 
appears therefore, that only dimer molecules are recognized 
to be packaged for transport from the endoplasmic reticulum 
to the Golgi apparatus where processing continues. The hy- 
pothesis that tunicamycin causes the accumulation of mono- 
meric vWf in the endoplasmic reticulum is further supported 
by  strong  perinuclear  immunofluorescence  staining  and  a 
gradual decrease in  Weibel-Palade body number (11;  also, 
our unpublished observations). 
Tunicamycin inhibition of vWf transport and processing is 
specific to human endothelial cells,  since precursor subunits 
are cleaved and  secreted by bovine cells in  the presence of 
tunicamycin (17). A tunicamycin-preincubation period of >3 
h  was  necessary  to  inhibit  N-linked  glycosylation.  When 
tunicamycin treatment was initiated simultaneous with met- 
abolic  labeling,  both glycosylated and  nonglycosylated pre- 
cursor subunits were produced, and cleavage of the former to 
a 220,000-mol-wt subunit occurred (not shown). This could 
explain the observation by Hormia et al. of  three distinct vWf 
bands  in  reduced  samples  of tunicamycin-treated  human 
endothelial cells (11). 
The presence oftunicamycin resulted in human endothelial 
cell  cultures  with  the  phenotype of severe von  Willebrand 
disease, i.e. absence of secretion of vWf. Subtle changes in the 
vWf gene,  translated into  missing glycosylation sites,  could 
produce a similar effect in vivo. 
Acidic pH Is Necessary for Multimerization of v Wf 
and for Formation of Weibel-Palade Bodies 
Our previous study (33) on biosynthesis of vWfin the presence 
of the  carboxylic  ionophore  monensin  (29)  demonstrated 
inhibition  of all the  processing steps localized to the Golgi 
apparatus. However, the exact mechanisms of this inhibition 
are  not  known.  It has been  shown  that  the  Golgi vesicles 
contain a proton pump capable of creating a transmembrane 
pH gradient (10)  and since monensin dissipates such a gra- 
dient (2, 4), some of the inhibitory effects of monensin might 
reflect its action on the pH of  the Golgi cisternae. We therefore 
decided to compare the effect of a weak base (25) with that 
of monensin on vWf  processing and secretion. The difference 
was striking in that monensin blocked all the Golgi-localized 
processing steps (33) while the weak base completely inhibited 
only the interdimer disulfide bond formation (Figs. 3 and 4). 
It appears that monensin acts on the Golgi apparatus by at 
least two different disruptive mechanisms, only one of which 
is abolishment of a  pH gradient that can be replicated by a 
weak base. Anderson and Pathak have demonstrated by im- 
munocytochemical techniques that the trans-Golg~  apparatus 
and the forming secretory vesicles are acidic (l).  Thus, the 
pH-sensitive multimerization of vWf dimers (Fig.  3) can be 
localized to  the  trans-Golg~ apparatus  and  possibly to  the 
Weibel-Palade bodies. Two observations lead us to the con- 
clusion that at least some multimerization takes place in the 
Golgi apparatus and that not all multimers are formed in the 
Weibel-Palade bodies. First, multimers larger than dimers are 
produced in the presence of 10  -8 M  monensin (33)  or 5  x 
10  -3  M  ammonium  chloride  (Fig.  3),  but  Weibel-Palade 
bodies are not found in cells treated in this manner (11) (Fig. 
5). Second, while only one of the two pathways for secretion 
of vWf  by endothelial cells involves the Weibel-Palade bodies 
(16),  the  protein  secreted  by both  pathways is  multimeric 
(Sporn L. A.,  V. J. Marder, and D. D. Wagner, manuscript 
submitted for publication). Conversion of high mannose to 
complex type carbohydrate is initiated in the central cisternae 
of the Golgi stack (7), consistent with the lack of inhibitory 
effect of ammonium chloride  on  this processing step (Fig. 
4 b). The pH in the trans-Gol~ apparatus is probably regulated 
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be reflected by incomplete multimerization of vWf, resulting 
in the phenotype of type IIA von Willebrand disease. 
The effect that the weak base had on storage of vWf in the 
Weibel-Palade bodies was not entirely unexpected. There are 
two other examples where the presence of a weak base inter- 
feres with the targeting of proteins. Newly synthesized lyso- 
somal enzymes are secreted instead of delivered to the lyso- 
some  in  the  presence  of chloroquine  (13)  and  ACTH  is 
secreted  through  a  constitutive  pathway  rather than  being 
stored in secretory granules in cells treated with chloroquine 
(19).  Despite  the differences  in  size  and  function  of these 
molecules, i.e., lysosomal enzymes, a peptide hormone and a 
large adhesive glycoprotein, a similar pH-dependent mecha- 
nism appears to control their sorting.  Perhaps low pH is a 
fundamental requirement for specific binding between a car- 
rier protein (l 3) and the molecule to be delivered to a storage 
or lysosomal vesicle. 
The small amount (20%) of inhibition of precursor cleavage 
observed  with  high  concentrations of ammonium chloride 
(Fig. 4 a) could be due to dilution of the substrate and enzyme 
as the Golgi apparatus dilates under the effect of the drug (6) 
or it could represent the amount of precursor that is removed 
during storage of the molecules (32). Still, even in the presence 
of 25  mM  ammonium chloride,  the  pro-sequence was  re- 
moved from most of the vWf subunits, and since multimers 
did not form under these conditions, it is unlikely that mul- 
timerization is a spontaneous process initiated by prosequence 
removal. 
To conclude, we have identified two important conditions 
in the biosynthesis of the large multimers ofvWf: the addition 
of N-linked carbohydrate in the endoplasmic reticulum and 
the acidic pH in the trans-Golgj apparatus and possibly Wei- 
bei-Palade bodies. Interference with these conditions in tissue 
culture by the use of tunicamycin and a weak base, respec- 
tively,  produced changes in endothelial cells that were phe- 
notypically similar to those found in von Willebrand disease. 
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